Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, White TP, Cao Y, Roccaro AM, Sacco A, Demos MG, Guerrera ML, Kofides A, Liu X, Xu L, Patterson CJ, Munshi M, Tsakmaklis N, Yang G, Ghobrial IM, Branagan AR, Castillo JJ.
Treon SP, et al.
Blood. 2021 Oct 28;138(17):1535-1539. doi: 10.1182/blood.2021012953.
Blood. 2021.
PMID: 34289017
Free PMC article.
Clinical Trial.